Ascletis, Inc.
1785 Jianghai Road,building No.1
Suite 804
Binjiang District
Hangzhou
China
Tel: +86-571-8538-9729
Website: http://ascletis.com.cn/
84 articles about Ascletis, Inc.
-
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
3/11/2024
Ascletis Pharma Inc. announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase inhibitor for treatment of acne, at the 2024 American Academy of Dermatology Annual Meeting in San Diego, the United States.
-
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
1/24/2024
Ascletis Pharma Inc. announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.
-
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
12/5/2023
Ascletis Pharma Inc. announces initiation of the Phase III clinical trial of fatty acid synthase inhibitor ASC40 for treatment of moderate to severe acne vulgaris.
-
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
11/9/2023
Ascletis Pharma Inc. announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
-
Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
11/6/2023
Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc. announces that the safety, pharmacokinetics, and pharmacodynamics data of ASC42, a novel farnesoid X receptor agonist, in healthy subjects have been published on the journal Drugs in R&D.
-
Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
9/26/2023
Ascletis Pharma Inc. announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma.
-
Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science
7/25/2023
Ascletis Pharma Inc. announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus infection at the 12th International AIDS Society Conference on HIV Science in Brisbane, Australia, and virtually.
-
Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
6/26/2023
Ascletis Pharma Inc. announces the poster presentation of ASC42, a novel farnesoid X receptor agonist, in combination with PEGylated interferon and entecavir in chronic hepatitis B patients with 12-week treatment at European Association for the Study of the Liver CONGRESS 2023.
-
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
5/8/2023
Ascletis Pharma Inc. announces that the China National Medical Products Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus infection.
-
Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index
2/27/2023
Ascletis Pharma Inc. announces that it will be included in the Hang Seng Hong Kong-Listed Biotech Index, effective from March 13, 2023.
-
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
1/31/2023
Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus infection.
-
Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19
1/16/2023
Ascletis Pharma Inc. announces dosing of 4 healthy subjects of the first cohort in multiple-dose escalation Phase I clinical trial of oral 3-chymotrypsin like protease inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19.
-
Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints
1/2/2023
Ascletis Pharma Inc. was recently informed that on December 29, 2022, Viking Therapeutics, Inc., a pharmaceutical company in the United States, filed certain complaints against Ascletis, its founder Dr. Jinzi Jason WU and certain subsidiaries of Ascletis in connection with the drug candidates ASC41 and ASC43F.
-
Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives
12/19/2022
Ascletis Pharma Inc. announces that it has received the Notice of Issuance from the United States Patent and Trademark Office for the patent application of oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus.
-
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
12/7/2022
Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19.
-
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
11/30/2022
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the completion of 180 patient enrollment for the Phase II clinical trial of ASC40 (denifanstat) for treatment of moderate to severe acne. The study is currently still blind.
-
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
11/23/2022
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19.
-
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
10/10/2022
Ascletis Pharma Inc. announces dosing of 24 healthy subjects of the first 3 cohorts in multiple-dose escalation Phase I clinical trial of oral RNA-dependent RNA polymerase inhibitor ASC10 for COVID-19 at the National Medical Center for Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University.
-
Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
10/5/2022
Ascletis Pharma Inc. announces dosing of the first patient in the 52-week Phase II clinical trial of thyroid hormone receptor β agonist ASC41 for treatment of liver biopsy-proven non-alcoholic steatohepatitis patients.
-
Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection
9/15/2022
Ascletis Pharma Inc. announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus infection has completed the enrollment of 15 HIV infected patients.